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Studies of perinatal exposures to dioxin-like compounds (DLCs), coplanar polycyclic halogenated aromatics whose prototype is 2,3,7,8-tetra-
chlorodibenzo-p-dioxin (TCDD), have employed a variety of outcome measures to investigate effects on the reproductive/developmental, endocrine,
immune, and neurobehavioral systems. The effects include infertility, growth retardation, fetal loss, changed sexual differentiation, reduced cogni-
tive/motor function, dermatologic and other ectodermal effects, and decreased immune response. Significant biomarkers have included sperm
count; CD4/CD8 ratio; and levels of testosterone, T4, and dopamine. Using specific dioxin or PCB congeners, these and other markers were used to
investigate the mechanisms of the observed effects. The DLCs, which include some PCB congeners, are characterized by high-affinity binding to
the Ah receptor; most biological effects are thought to be mediated by the ligand-Ah receptor complex. Other PCB congeners have low affinity for
the Ah receptor, and operate by non-Ah receptor mechanisms. The biologic activity of a PCB mixture is the sum of the agonist and antagonist activi-
ties of the different constituents in the mixture. Animal studies with specific PCB congeners can help to clarify these activities. With similar
approaches, biologic markers of effect can be developed and applied in epidemiologic studies to monitor for, and predict, adverse effects in
humans. - Environ Health Perspect 103(Suppl 2):161-167 (1995)
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Introduction
A biologic marker, or biomarker, is gener-
ally defined as any functional or biochemi-
cal change in a cell or tissue that is indica-
tive of exposure, response or potential sus-
ceptibility to a drug or an environmental
agent (Figure 1) (1). Generally, biomarkers
are laboratory-based measures that are
intended to increase the sensitivity, speci-
ficity, or power of a study to establish a
causal association between an exposure and
an outcome, and/or provide useful infor-
mation about the mechanisms involved in
exposures, responses, or susceptibilities.
This workshop focused on exposures to
a subset of the polycyclic halogenated aro-
matic hydrocarbons, which include the
polychlorinated biphenyls (PCBs), poly-
chlorinated dibenzo-p-dioxins (PCDDs),
and polychlorinated dibenzofurans
(PCDFs) (Figure 2). The latter compounds
are by-products of industrial syntheses and
chlorine bleaching processes, and can be
produced through burning ofmunicipal or
industrial waste. Many are persistent envi-
ronmental contaminants, the most toxic
and well studied of which is 2,3,7,8-tetra-
chlorodibenzo-p-dioxin (TCDD). The
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workshop reviewed the evidence that peri-
natal exposures to these compounds may
lead to adverse health outcomes.
Biomarkers of Exposure
Many of the dioxins, dibenzofurans and
PCBs resist biodegradation and, because
they are lipophilic, concentrate in adipose
tissues. Tissue concentrations of these par-
ent compounds serve as good measures of
environmental exposures, and residue levels
in body fat or in lipid fractions of breast
milk or blood are used to quantify this
exposure. A vast literature describes the lev-
els of organochlorine residues found in
body fluids or tissues of animals and
humans, and documents the increased con-
centration ofthese contaminants in the fat
of animals at successively higher trophic
levels ofthe food chain.
The residue profile (nature and levels of
residues) in tissues is unlikely to be identi-
cal to the composition ofthe original envi-
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ronmental mixture because different indi-
vidual components of this mixture may be
taken up and metabolized at different rates
by the organism. For example, octachloro-
dioxins are absorbed via the gut much
more poorly than tetrachloro congeners,
and consequently are under-represented in
the residue profile in tissues.
Biomarkers of Effect
The attractiveness ofbiomarkers ofeffect as
surrogates of disease is that they can pro-
vide an indication of increased likelihood
of a disease outcome before clinical symp-
toms appear. Ideally, the application of
such markers is simple, quick, and inex-
pensive and can trigger early preventive
measures. Such measures can bring major
public health benefits ifthey are directed to
diseases of long latency, particularly those
that are either life-threatening (e.g., cancer),
cut offproductive life years (e.g., reproduc-
tive/developmental, neurobehavioral
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Figure 1. Schematic of continuum of biologic markers.
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Figure 2. Structures ofthe polycyclic halogenated aromatic hydrocarbons (DLCs and non-DLCs).
disorders), or have great medical or social
costs (e.g., Alzheimer's disease). Thus, bio-
markers ofeffect
* signal that an adverse clinical effect has
the potential to occur;
* identify exposed or responsive individuals;
* help to develop preventive measures by
giving more detailed information (e.g.,
mechanism) on the health problem;
* help to develop regulatory strategies for
disease prevention (e.g., regulations
based on biomarker end points).
Identifying Biomarkers of
Effect and Susceptibility:
Understanding Disease
Mechanism(s)
A key to identifying a suitable biomarker of
effect or susceptibility is having a good
understanding ofthe mechanisms) bywhich
the adverse health outcome arises. In the
medical model, the adverse outcome is dis-
ease, and is accompanied by the disease
pathway paradigm: predisposing condi-
tions, early warning symptoms, preclinical
indicators and, finally, clinical symptoms.
Some adverse outcomes (e.g., neurobehav-
ioral) are not easily characterized as a series
of stages on a pathway to an abnormal
pathology or disease, and may not fit this
model; instead they may represent an
impaired capacity within what is consid-
ered the normal range (e.g., lowered IQ:
see "Issues").
Optimally, a marker of exposure indi-
cates that the agent has access to the causal
mechanism; an effect marker is an element
of this mechanism; and a marker of sus-
ceptibility bears some relationship to this
mechanism. Rarely, however, is our
knowledge of disease mechanisms suffi-
cient for us to declare that a marker is
strongly associated with either disease sus-
ceptibility or outcome. Instead, we place a
marker on the continuum of biomarkers
(exposure, early biological effect, or effect)
depending upon the weight of evidence
that connects the biologic measure with
the disease outcome. The predictive value
of any marker of effect depends upon the
strength of evidence that links it with the
adverse health outcome.
Most markers lack a strong enough
association with disease outcome to be clas-
sified as markers of effect; consequently, if
their response is found to vary proportion-
ally with dose, they are classified as either
markers of exposure or as markers of early
biologic effect. Chromosomal aberrations,
for example, are considered markers ofearly
biologic effect rather than ofcancer because
our knowledge oftheir specific role in can-
cer causation is limited (2). Lowered sperm
count, on the other hand, is a marker for
infertility because it has a demonstrated
relationship with this outcome (3-5).
Mechanism(s) of Action of
Dioxin-like Compounds
(DLCs): The Ah Receptor
Most cells contain a cytoplasmic protein,
called the Ah receptor, which has a high
affinity for TCDD (6). Other compounds
that bind to the intracellular Ah receptor are
termed dioxin-like compounds (DLCs).
These include representatives of the copla-
nar, halogen-substituted multiring structures
such as the PCDDs, PCDFs, and some of
the coplanar PCB congeners. Most PCB
congeners that are noncoplanar are reported
to have lowaffinity for theAh receptor.
The TCDD-Ah receptor complex is
believed to mediate many of TCDD's
observed effects. The DLC-Ah receptor
complexes produce a characteristic spec-
trum of responses in animal models. The
potency of DLCs as effectors of terato-
genicity, carcinogenicity, immunotoxicity,
and biochemical changes (drug-metaboliz-
ing enzymes and growth factor pathways)
strongly correlates with their binding affin-
ity to theAh receptor (7-10).
The binding ofa molecule ofligand to
the cytoplasmic Ah receptor results in acti-
vation ofthe receptor and translocation to
the nucleus. This is a complex event in
which heat shock proteins dissociate from
the receptor and another protein, Ah
receptor nuclear translocator (ARNT)
associates with the receptor. The
ligand-AhR-ARNT complex acts as a
transcriptional enhancer: it binds to regu-
latory regions on DNA, upstream of the
CYPJAJ gene and other dioxin-responsive
genes, and increases the transcription of
these genes (11,12). The altered transcrip-
tion of genes in the ligand-Ah-responsive
gene battery is believed to be the mecha-
nism by which DLCs produce their bio-
logical effects (13).
Non-DLCs operate by unknown mech-
anisms. Some non-DLCs are more active
in producing certain biologic responses
than related DLCs. For example, a non-
coplanar PCB congener, PCB 28, is more
active in altering dopamine levels in the
forebrain of rats than dioxin-like coplanar
PCB congeners (14). This suggests that the
neurochemical response is mediated by a
non-Ah receptor mechanism, which is con-
sistent with the reported absence ofthe Ah
receptor from neurons (15).
The discussion below summarizes
studies that employ a variety ofmarkers of
effect to investigate disease outcomes. Only
a few are directly linked to outcome (e.g.,
sperm count and infertility). Most markers
described below signal changes in functions
but are not yet strongly linked to specific
adverse outcomes. For example, CD4/CD8
ratios, or levels of T4 or dopamine, are
now considered markers of early biologic
effects. Future studies may link them to
adverse outcomes such as immune system
depression or motor/cognitive deficits.
CYPIA] activity is also considered a mark-
er of early biologic effect (DLC bound to
the Ah receptor), lacking a known associa-
tion with disease.
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Biomarkers and
Perinatal Studies
Perinatal exposures encompass prenatal
(transplacental) as well as postnatal (lacta-
tional) exposures. What is unusual about
the application of biomarkers to the study
ofperinatal exposures?
Perinatal exposures are unique in that
they impact upon organ systems that are in
varying stages ofdevelopment. The respons-
es exhibited by these developing systems, for
example, to perinatal exposures to DLCs are
influenced by several factors including: the
chemical nature of the agents; the timing
and duration of the exposure during the
developmental period; and the interrelation-
ships between the developing systems. The
broad range ofresponses that DLCs produce
in multiple developing organ systems sug-
gests that DLCs act via a central mechanism
(e.g., hormonal) and that the developing
systems interact.
In 1968 researchers discovered ectoder-
mal abnormalities and cognitive/motor
deficits among children who had accidental
perinatal exposure to DLCs and non-DLCs
in cooking oil (16-18). Since then,
researchers have sought to do the following:
* characterize the full range of clinical
effects arising from perinatal exposures
to these compounds;
* identify the mechanisms) of action of
these compounds in causing seemingly
disparate effects;
* understand the interrelationship ofthese
effects in developing systems;
* investigate the mechanisms) and the
interrelationships between these complex
clinical outcomes using biomarkers of
exposure, susceptibility and effect.
Animal Studies
As reported in the workshop, perinatal
exposures to DLCs in animal studies have
provided information on effects in several
developing systems, including the repro-
ductive, endocrine, neurobehavioral, and
immune systems. Adverse reproductive or
developmental effects included reduced fer-
tility in primates (19), endometriosis in
primates (20), altered sexual differentiation
in male and female rats (21-23), reduced
sperm count in rats (24), and growth retar-
dation in primates and rats (19,25). In the
endocrine system, the effects included
reduced T4 levels in the prefrontal cortex
of rats (25), reduced testosterone levels in
rats (22,23), and altered dopamine levels
in the forebrain of primates and rats
(14,26,27). Neurobehavioral effects
included spatial learning/memory deficits
in primates and rats (27-30).
In the immune system, DLCs act as
immunosuppressors and immunoenhancers
in rats and mice (31), affecting mainly
T-cell responses (31-33), although effects
on other cells of the immune system are
reported (34-36). There is suggestive evi-
dence that DLCs affect the primary
immune response by changing the
CD4/CD8 ratio (the ratio of helper T to
suppressor T cells) or the ratio ofotherlym-
phocytesubpopulations (31-33,37-40).
For several ofthe effects seen in animal
studies, there appear to be corresponding
outcomes in humans: reductions in infant
height and primary immune response in
Inuit infants whose mothers had breast
milk with high PCB levels (41,42); and
reductions in cognitive or motor functions
in infants whose mothers ingested PCB-
contaminated cooking oil or fish during
pregnancy or lactation (16-18,43,44).
Biomarkers and Mechanisms
The wide range of effects seen in different
organ systems of animals and humans
underlies the current working hypotheses
about the mechanisms of action of DLCs
and non-DLCs (see Workshop Summary
Report, this issue) including the following:
* Biologic effects ofDLCs are mediated by
their binding to the Ah receptor, while
the mechanisms of action of non-DLCs
are not well understood;
* DLCs act as "environmental hormones,"
disrupting normal endocrine functions.
* Pluripotent effects on the reproduc-
tive/ developmental, endocrine, neu-
robehaviorial, and immune systems
reflect the hormone-like activities of
DLCs and non-DLCs as well as the
highly integrative and interactive nature
ofthese systems.
* DLCs, as hormones, affect the differentia-
tion ofcells in various systems in a tissue-,
cell-, and stage-specific manner; effects
consequently are tissue-, cell-, and stage-
dependent; and timing ofexposure can be
critical to the expressed outcome. For
example, a cell mayexpress DLC-sensitive
receptors for only a limited period in its
life cycle.
* The perinatal period is a sensitive period,
a window through which one may exam-
ine the effects ofDLCs on several devel-
oping organ systems.
As seen in Table 1, a variety of bio-
markers have been measured in each bio-
logical system (see Lindstrom et al., this
supplement, for their use in specific stud-
ies). Results from these studies give insight
into mechanisms ofaction ofDLCs during
the perinatal period.
Reproductive
Perinatal exposures to TCDD (and pre-
sumably DLCs) produce reproductive
effects in male offspring that are different
from those produced by PCB mixtures
(presumably the non-DLC components):
PCBs cause infertility in primates without
decreasing the sperm count (19); TCDD
lowers sperm count in rats without affect-
ing fertility (22-24). The differences in
response are attributable either to species
differences or to differing mechanisms of
actions of TCDD and PCBs. TCDD acts
via the Ah receptor; some PCB congeners
may act via non-Ah receptor mechanisms.
Endocrine
Prenatal TCDD in rats causes feminization
and demasculinization ofmale offspring, as
manifested by patterns ofLH secretion and
sexual behavior (21-23). Brain levels ofT4
(thyroid hormone) and dopamine (neuro-
transmitter) were reduced in rats by perina-
tal exposures to specific noncoplanar (non-
DLC) PCB congeners (14,25-27).
Dopaminergic effects were, in addition,
age-dependent (26). Since T4 crosses the
placenta and blood-brain barrier, changes in
T4 hormone levels in the fetus may affect
normal development in the brain (e.g.,
branching of apical dendrites). Studies in
rats of the effect ofspecific PCB congeners
on T4 and dopamine levels, apical dendrite
development, and memory test scores could
explore the relationship between these bio-
markers and health outcomes.
Immune
Cells within the immune system are contin-
ually replenished and are a model for devel-
opmental effects and effects on differentia-
tion. The DLCs can act as immuno-sup-
pressors or enhancers in this system,
depending upon the cellular target. The
effects ofDLCs on macrophages suggest an
enhancement of inflammatory activity and
expression of cytokines, particularly TNF
and IL-i (35,36,45,46). The effects of
DLCs on B-cells results in suppression of
antibody production and a direct effect on
phosphorylation in this cell type (34,47,48).
One of the most common observations is
for a suppression ofthe anti-SRBC plaque-
forming cell responses in TCDD exposed
mice, which may be due to suppression of
T-cell responses, although these effects are
not observed in rats (31,49).
Changes in cell surface markers on T-
cells are apparently a particularly sensitive
response to the effects ofTCDD in nonhu-
man primates, and have resulted in explo-
ration of this effect as a biomarker in
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Table 1. Biomarkers and their functions.
Area/biomarker Function
General
Ah receptor An intracellular binding protein of DLCs which, when attached to a ligand and other
binding proteins, is documented to mediate many ofthe effects of DLCs. At least 27
genes/gene products are controlled by the Ah receptor, including CyplA1 and CyplA2
(cytochrome P450s(; Gst-Ya(glutathione S-transferase); Nmo-1 (menadione oxidore-
ductase); T-ALDH (aldehyde dehydrogenase); and PA-2 (plasminogen activator
inhibitor-2) (13).
ARNT Ah receptor nucleartranslocator is a protein that binds to the ligand-Ah receptor
complex as the heat shock proteins dissociate from the complex, forming a
ligand-Ah receptor-ARNT complex. This new complex is translocated from the cyto-
plasm to the nucleus, where it acts as a transcriptional enhancer by binding to regu-
latory regions of the DNA.
CYPlAl Drug-metabolizing enzyme (formerly P450) induced by DLCs through binding to the Ah
receptor.
Reproduction
Birth weight/ Growth retardation
bodyweights
Sperm count Risk of infertility
Endocrine
5a-dihydrotestosterone Testosterone metabolite; binds tightly to androgen receptor.
Estrogen receptors
Testosterone
Thyroid
T3
T4
FT4
114
TBG
TRH
TSH
Neurobehavioral
Bayley
McCarthy
SDAtask
Immune
CD4/CD8
CD4/CD29
SRBC PFC
Stress protein
TdT/RAG
TNF
Intracellular receptors decreased by DLCs.
Steroid hormone (androgen); needed atcritical periods fordevelopment of male
morphologic and behavioral sexual characteristics.
T3 and T4 are the growth hormones that regulate development and energy metabolism;
their synthesis and secretion occurs via secretion ofTRH and TSH. Secretion of both
TRH and TSH, in turn, is suppressed bythyroid hormone; this feedback inhibition pre-
vents hormone concentration from rising too high.
Triiodothyronine; metabolite ofthyroxine; growth hormone similarto T4 butfourtimes
as potent.
Thyroxine; unlike T3, passes blood-brain barrier.
Free, as opposed to bound, T4; synthesis ofT3 and T4 occurs within thyroglobulin from
tyrosine residues.
Total T4(bound+free).
Thyroxine binding globulin; synthesized in liver; majorthyroid hormone binding trans-
port protein for humans; absent in rats.
TSH (thyrotropin)-releasing hormone produced by hypothalamus (HT), which controls
the release ofTSH bythe anterior pituitary; secreted by HT neuroendocrine cells into
blood vessels of pituitarystalk, and travels to pituitary, where it stimulates cells to
release TSH into main bloodstream.
Thyroid-stimulating hormone; produced by anterior pituitary; stimulates cells in thyroid
to synthesize and secretethyroid hormone, which travels in blood to mostcells of body;
regulates thyroid function.
Measure ofcognitive and motorability(up to age 2).
Measure of cognitive and motorability(age 3-5yrs).
Spatial delayed alternation task; measures spatial learning/memory impairment in pri-
mates and rodents.
Cell surface markers on T-("thymus") lymphocytes; ratio of "helper" T/"suppressor" T
indicates immune function (2="normal"; <1 =compromised).
CD29 are "memory" T-cells subsetthat have been previously activated byantigens;
possible marker ofsensitivity or effect to DLC exposures.
Sheep red blood cell plaque-forming cell assayforability of B-cells to produce antibody
againstantigen; most sensitive assayfor effects of DLCs in mice.
Family of proteins (includes TNF)synthesized in many cells in response to infections,
inflammation, and stress; general effectors on metabolism and homeostasis.
Markers for stem cells oflymphocytes in bone marrow; used to demonstrate that DLCs
affect development ofT-cells.
Tumor necrosis factor, produced by macrophages, is an immune system hormone(lym-
phokine) involved in inflammatory response; in animals, DLCs increase TNF and cause
toxic effects (weight loss, death).
humans (39,50,51). DLC exposures
change the ratios of lymphocyte subpopu-
lations in rodents and primates
(31-33,37-40), perhaps impairing the pri-
mary immune response and accounting for
the decreased immunization "take" rates
reported for Inuit children (41,42).
Changes in the ratio of lymphocyte sub-
populations (e.g., changed CD4/CD8
ratio) may mean that DLC and/or non-
DLC components of PCB mixtures alter
the differentiation pattern of cells of the
immune system.
A mechanism for TCDD-induced
thymic atrophy is suggested by a study in
mice in which the depletion of bone mar-
row prolymphocytes (stem cells) following
TCDD exposure was measured using
markers that are specific for prolympho-
cytes (terminal deoxynucleotidyl trans-
ferase, TdT, and recombinase activating
gene, RAG) (32,33). In addition to reduc-
ing the number oflymphocytes in the thy-
mus gland, TCDD appears to reduce the
number ofprothymocytes in the bone mar-
row available to repopulate the depleted
thymus. In this way, TCDD's effects on
bone marrow are believed to contribute to
thymic atrophy.
Neurobehavioral
Perinatal studies with specific PCB con-
geners and biomarkers suggest a link
between behavioral changes in rodents and
primates with changes in levels of T4 or
dopamine. For example, spatial learning/
memory deficits in monkeys and adult rats
are produced by perinatal exposures to spe-
cific PCB congeners, especially PCB28
(Schantz), a non-DLC ortho-substituted
congener. This same congener also alters
dopamine levels in monkeys and rats in
specific regions ofthe brain (26).
Issues
For perinatal exposures, are there markers
of early events that predict later adverse
human health outcomes? Can these mark-
ers be used to study delayed effects, i.e.,
predict adverse consequences in newborns
and young children, in adults and possibly
second generation children? Are these
markers linked to exposure? Do they sug-
gest possible public health interventions?
Two examples from the workshop illus-
trate the difficulties ofestablishing associa-
tions between biomarkers and disease out-
comes. Human data suggest that exposure
to DLCs changes the ratio of lymphocyte
subpopulations (e.g., CD4/CD8 ratio).
These changes fall within the range ofvari-
ation seen in normal, "unexposed" human
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populations. As a consequence, we do not
know if they signal an adverse health out-
come. If the changes fall outside the nor-
mal range, their health significance is still
not clear. Are they associated with an
adverse outcome? Should we consider a sig-
nificantly altered lymphocyte subset ratio
an adverse health outcome? How big must
the change be?
The second example illustrates difficul-
ties with outcome variables that integrate
functions, such as IQ. A shift in an individ-
ual's IQ of a few points is not statistically
significant and has little impact on the
individual or on society. A decrease oftwo
points in population IQ, however, can sig-
nificantly impact public health. Do we
have candidate markers that can predict
this shift? Could changes in neurotransmit-
ter levels (e.g., dopamine in forebrain or
caudate nucleus) or other effects in the
developing or adult brain be used to pre-
dict changes in IQ?
Workshop participants emphasized
the difficulties in linking chemical expo-
sures with complex responses that have
multiple causes (e.g., neurobehavioral end
points). For these responses, chemical
exposures may not be the primary causes,
and their effects may be obscured or con-
founded by stronger factors.
(Alternatively, they may work in concert
with other factors to produce an effect.)
For example, neurobehavioral studies sug-
gest there is an association between peri-
natal exposures to DLCs and changes in
IQ in children. However, many socioen-
vironmental factors also affect IQ, and
these may overwhelm and mask any con-
tribution that is made by a chemical
exposure. They act as confounders of
chemical exposures. Before chemical link-
ages can be investigated, neurobehavioral
measures are needed that can better control
for social/environmental factors.
Finally, neurobehavioral researchers cite
drawbacks in the application ofbiomarkers
to their field. First, the medical model of
disease, in which there is a pathway from
early health impairment (preclinical signs)
to frank pathology and disease, may not be
applicable to neurobehaviorial end points.
The various neurobehavioral "biomarkers,"
such as IQ, age at development of verbal
skills, or short-term memory, are not con-
sidered precursors or early signs of disease.
They are effects that are less favored.
Decrements in these functions do not signal
a transition from "normal" to "abnormal",
but rather a shift to a less favorable position
within the "normal" range.
The sensitivity and specificity of bio-
markers in neurobehavioral studies was also
questioned. The most useful cognitive mea-
sures are those for which population norms
have been established. These measures gen-
erally sum the influences ofa variety offac-
tors that can affect development. They do
not assay the functioning or non-function-
ing ofspecific neurobehavioral mechanisms.
More specific tests are needed. Importantly,
a more complete understanding of the
mechanisms involved in the neurobehav-
ioral changes themselves is needed before
more specific tests can be developed.
Epidemiologic Studies
in Progress
Several ongoing epidemiologic studies
investigate the effects ofperinatal exposures
to DLCs and non-DLCs by employing a
number of biologic markers. Koopman-
Esseboom et al. (52) explore the effects of
PCBs and dioxins on thyroid hormone
metabolism (TT3, TT4, FT4, and TSH
levels) and on neurologic and psychomotor
development among children whose moth-
ers had varying levels ofcoplanar PCBs and
TCDD in their breast milk.
Dewailly et al. (this supplement) exam-
ine markers ofexposure, effect, and suscepti-
bility among Inuit children (n= 200)
exposed to PCBs and heavy metals via fish
consumption. Levels of PCB congeners,
HCB, DDE, dieldrin, PCDD/PCDF, ortho,
andcoplanar PCBs, and metals (Hg, Pb, and
Se) are measured in breast milk, maternal
serum, placenta, and cord blood.
Biomarkers are measured in placenta and
cord blood including, in placenta: enzyme
induction (CYPlAl, CYP1A2) and Ah
receptor levels (binding assay with 3H
TCDD); and in cord blood/lymphocytes:
stress proteins (heat-shock proteins HSP90),
immunotoxic effects (natural killer cell
(NK) activity and CD4/CD8 ratio), sister
chromatid exchange (SCE), and endocrine
hormone levels (T4, T3, andTSH).
Buck et al. (this supplement) described
an ongoing retrospective study of repro-
ductive outcomes among 11,000 New
York state anglers 18 to 34 years of age.
End points examined for subsets of this
cohort include fertility rates (NYS live
birth and fetal death registries), sponta-
neous fetal mortality rates (NYS fetal death
registries), pregnancy intervals, intrauterine
growth retardation, secondary sex ratios,
time to conception, intrauterine growth
retardation, neurodevelopmental status,
and disorders ofectodermal tissue.
Rogan et al. (this supplement) examine
the lactational effects of DDE (levels mea-
sured in breast milk) in a cohort of 230
mothers in Mexico. Preliminary results sug-
gest that DDE acts as a prolactin antago-
nist. Rogan et al. continue to follow their
cohort of 117 children in Taiwan with reg-
ularphysical examinations to determine any
peripubertal developmental effects from
DLC exposures, including stages ofpuberty
(as per Tanner scale). In a similar manner,
they are also examining a cohort of 200
children born in Taiwan between 1985 and
1992 for peripubertal developmental effects
that mayresult from DLC-exposures.
Clark et al. (this supplement) examine
susceptibility markers in two cohorts, one
in Seveso, Italy exposed to high levels of
dioxins following a chemical plant explo-
sion in 1976 and the second in Germany,
with occupational exposures to dioxins in a
chemical plant that produces 2,4,5-
trichlorophenol. Within each of these
cohorts, certain individuals developed chlo-
racne. Others, in the same cohort with sim-
ilar exposures, did not. Genetic and bio-
chemical differences between the respond-
ing and nonresponding individuals are
sought to account for the differences in
response. These include Ah receptor levels
and the expression ofthe CYPlAl, TNFor
IL-1 beta genes.
Conclusions
The potential adverse consequences on the
reproductive, endocrine, immune, and neu-
robehaviorial systems ofperinatal exposures
to dioxins, dibenzofurans, and PCBs are
being explored using a variety of biomark-
ers, including sperm count, CD4/ CD8
ratio, and levels of testosterone, T4, and
dopamine. In animal studies, exposures to
some of the listed compounds produce
changes in the levels ofthese markers, sug-
gesting that the chemicals affect fertility,
impact the endocrine system, cause femi-
nization and demasculinization of males,
depress the immune system, and produce
neuroendocrine and neurobehavioral
effects. These and other markers will be
employed in future experimental studies to
explore the mechanisms of these effects. If
validated, these markers can be used in epi-
demiologic studies to determine the effects
in humans that arise from perinatal expo-
sures to dioxins, dibenzofurans, and PCBs.
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